Mariana Plazas Torrente

Prof. Mariana Plazas Torrente

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2017 in Science
Verified
Journal Article
Closed access
PDF file
SGStephanie N. Gates
Stephanie N. Gates
AYAdam L. Yokom
Adam L. Yokom
JLJiaBei Lin
JiaBei Lin
J Meredith Jackrel
Meredith Jackrel
ARAlexandrea N. Rizo
Alexandrea N. Rizo
DSDaniel R. Southworth
Daniel R. Southworth
Untangling aggregates one step at a time: Conserved AAA+ protein complexes exploit adenosine triphosphate hydrolysis to unfold and disaggregate their substrates in response to cell stress, but exactly how they do this has been unclear. Gates et al. determined high-resolution cryo-electron microscopy structures of the Hsp104 disaggregase bound to an unfolded polypeptide substrate in its channel. The structures reveal substrate interactions and two different translocation states. Hsp104 undergoes conformational changes that drive movement along the substrate by two-amino-acid steps. These states help explain how this molecular machine can solubilize protein aggregates and amyloids. Science , this issue p. 273

1 February 2019 in Translational Research
Verified
Journal Article
Closed access
SBSeth A. Bennett
Seth A. Bennett
RTRoyena Tanaz
Royena Tanaz
SCSamantha N. Cobos
Samantha N. Cobos
MTMariana Plazas Torrente
Mariana Plazas Torrente

1 August 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
SCSamantha N. Cobos
Samantha N. Cobos
SBSeth A. Bennett
Seth A. Bennett
MTMariana Plazas Torrente
Mariana Plazas Torrente

15 December 2017 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
KCKaren Chen
Karen Chen
SBSeth A. Bennett
Seth A. Bennett
NRNavin Rana
Navin Rana
HYHuda Yousuf
Huda Yousuf
MSMohamed Said
Mohamed Said
MTMariana Plazas Torrente
Mariana Plazas Torrente

13 September 2024 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
RFRaven M. A. Fisher
Raven M. A. Fisher
MTMariana Plazas Torrente
Mariana Plazas Torrente
Alzheimer’s disease (AD), Parkinson’s disease (PD), Frontotemporal Dementia (FTD), and Amyotrophic lateral sclerosis (ALS) are complex and fatal neurodegenerative diseases. While current treatments for these diseases do alleviate some symptoms, there is an imperative need for novel treatments able to stop their progression. For all of these ailments, most cases occur sporadically and have no known genetic cause. Only a small percentage of patients bear known mutations which occur in a multitude of genes. Hence, it is clear that genetic factors alone do not explain disease occurrence. Chromatin, a DNA-histone complex whose basic unit is the nucleosome, is divided into euchromatin, an open form accessible to the transcriptional machinery, and heterochromatin, which is closed and transcriptionally inactive. Protruding out of the nucleosome, histone tails undergo post-translational modifications (PTMs) including methylation, acetylation, and phosphorylation which occur at specific residues and are connected to different chromatin structural states and regulate access to transcriptional machinery. Epigenetic mechanisms, including histone PTMs and changes in chromatin structure, could help explain neurodegenerative disease processes and illuminate novel treatment targets. Recent research has revealed that changes in histone PTMs and heterochromatin loss or gain are connected to neurodegeneration. Here, we review evidence for epigenetic changes occurring in AD, PD, and FTD/ALS. We focus specifically on alterations in the histone PTMs landscape, changes in the expression of histone modifying enzymes and chromatin remodelers as well as the consequences of these changes in heterochromatin structure. We also highlight the potential for epigenetic therapies in neurodegenerative disease treatment. Given their reversibility and pharmacological accessibility, epigenetic mechanisms provide a promising avenue for novel treatments. Altogether, these findings underscore the need for thorough characterization of epigenetic mechanisms and chromatin structure in neurodegeneration.

17 November 2021 in Biochemistry
Verified
Journal Article
Closed access
SBSeth A. Bennett
Seth A. Bennett
SCSamantha N. Cobos
Samantha N. Cobos
MMMelagras Mirzakandova
Melagras Mirzakandova
MFMichel Fallah
Michel Fallah
ESElizaveta Son
Elizaveta Son
MTMariana Plazas Torrente
Mariana Plazas Torrente